Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACTICLATE CAP vs ARESTIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, blocking aminoacyl-t RNA binding.
Minocycline is a semisynthetic tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the addition of amino acids to the elongating peptide chain. This action is bacteriostatic. In periodontal disease, it also inhibits matrix metalloproteinases (MMPs), particularly collagenase, and suppresses inflammatory cytokine production, reducing tissue destruction.
Treatment of infections caused by susceptible bacteria, including respiratory tract infections, urinary tract infections, and acne vulgaris
Adjunctive treatment of periodontitis (subgingival administration by a dental professional),Off-label: Treatment of acne vulgaris, rosacea, rheumatoid arthritis (MRSA decolonization is not standard)
350 mg orally once daily, increased to 350 mg twice daily if no response after 2 weeks.
1 mg subgingival application per periodontal pocket, applied as a single dose by a dental professional.
Terminal elimination half-life 6-10 hours; prolonged in renal impairment (up to 22 hours in anuria)
The terminal elimination half-life of minocycline is 11-17 hours (mean ~16 hours). This long half-life allows for twice-daily dosing in systemic use, but for Arestin (subgingival), local sustained release provides prolonged local exposure.
Primarily hepatic; metabolites include 4-epimino derivatives; not significantly metabolized via CYP450.
Minocycline is extensively metabolized in the liver via multiple pathways, with at least 6 metabolites identified. The major metabolic routes include hydroxylation at the 9-position (via CYP450 enzymes, possibly CYP3A4) and N-demethylation. It also undergoes glucuronidation. The drug has a long half-life (11–17 hours) and undergoes enterohepatic recirculation.
Renal (60-70% as unchanged drug), fecal (20-30% as metabolites); minor biliary elimination
Minocycline is primarily eliminated via hepatic metabolism and biliary/fecal excretion. Renal excretion accounts for approximately 10-20% of the dose, with the remainder excreted in feces via bile. Less than 10% is recovered unchanged in urine.
90-95% bound to serum proteins, primarily albumin
Minocycline is approximately 70-75% bound to plasma proteins.
0.75 L/kg (50-70 L in adults); distributes well into tissues including bone, teeth, and synovial fluid
Volume of distribution for minocycline is 1.0-1.3 L/kg, indicating extensive tissue penetration, consistent with its lipophilic nature and ability to concentrate in various tissues including gingival crevicular fluid.
Oral: 90-100% (capsule); food or dairy reduces absorption by up to 50%
Subgingival administration: Direct local delivery results in negligible systemic absorption (bioavailability <1% relative to oral dose). Oral minocycline bioavailability is approximately 90-100%.
e GFR 30-59 m L/min: 350 mg once daily; e GFR <30 m L/min: not recommended.
No dose adjustment required for renal impairment.
Child-Pugh A: no adjustment; Child-Pugh B or C: 175 mg once daily.
No dose adjustment required for hepatic impairment.
Not established for children <12 years; for ≥12 years, same as adult dosing.
Not recommended in pediatric patients below 18 years of age due to lack of safety and efficacy data.
Initiate at 175 mg once daily; titrate cautiously based on renal function.
No specific dose adjustment; use with caution due to potential age-related comorbidities.
Photosensitivity: severe sunburn can occur with sun exposure; discontinue if photosensitivity occurs. Tooth development: use during tooth development (last half of pregnancy, infancy, childhood to age 8) may cause permanent tooth discoloration. Bone growth: may retard bone growth in premature infants. Renal toxicity: may cause azotemia, hyperphosphatemia, and acidosis. Avoid in renal impairment.
None.
Photosensitivity, tooth discoloration, bone growth retardation, renal impairment, hepatotoxicity, increased intracranial pressure, superinfection, and use in pregnancy/lactation.
Photosensitivity: May cause exaggerated sunburn; avoid prolonged sun exposure.,Superinfection: Use may result in overgrowth of nonsusceptible organisms, including fungi.,Hepatotoxicity: Rare cases of liver injury; discontinue if symptoms occur.,Renal impairment: Use with caution in renal dysfunction; may accumulate.,Autoimmune syndromes: Cases of drug-induced lupus, serum sickness-like reactions, and vasculitis reported.,Intracranial hypertension: Associated with minocycline; symptoms include headache and blurred vision.,Tooth discoloration: May cause permanent discoloration of teeth in children under 8 years.,Bone development: Use during pregnancy may affect fetal skeletal development.
Hypersensitivity to tetracyclines, pregnancy, breastfeeding, children under 8 years, renal impairment, and concurrent use with oral retinoids.
Hypersensitivity to any tetracycline antibiotic.,Pregnancy (especially second and third trimesters) – risk of fetal harm.,Lactation – excreted in breast milk, potential for adverse effects in nursing infants.,Children under 8 years of age – risk of permanent tooth discoloration.
Avoid food and beverages for at least 1 hour before and after administration, as they can reduce the efficacy of activated charcoal. Do not mix with milk or ice cream, as they decrease binding capacity. Administer with water or a non-carbonated, non-alcoholic drink.
No known food interactions. Patients should avoid hard, crunchy, or sticky foods for at least 7 days after application to prevent mechanical disruption of the microspheres.
First trimester: Category D; tetracyclines can cause fetal harm including inhibited bone growth and discoloration of teeth (yellow-gray-brown). Second and third trimesters: Known to cause permanent tooth discoloration (enamel hypoplasia) and reversible inhibition of bone growth; use contraindicated after 15 weeks gestation.
ARESTIN (minocycline hydrochloride) is a tetracycline antibiotic. Class D: Positive evidence of human fetal risk. Use contraindicated in pregnancy. Risk is highest in second and third trimesters due to tetracycline deposition in fetal bones and teeth, causing permanent discoloration and enamel hypoplasia. Potential for reversible inhibition of bone growth. First trimester exposure may be associated with neural tube defects and cardiac malformations, though data are limited.
Tetracyclines are excreted in breast milk but absorption by the infant is limited due to chelation with milk calcium; M/P ratio for doxycycline is approximately 0.3-0.4. Theoretical risk of tooth staining and bone inhibition, but clinical significance is low with short-term use; caution with prolonged therapy.
Minocycline is excreted into human breast milk with an M/P ratio of approximately 0.6 to 0.8. Theoretical risk of permanent tooth discoloration and bone growth inhibition in nursing infants. Avoid use in breastfeeding women; if necessary, consider temporary cessation of breastfeeding. Alternative antibiotics are preferred.
No dosage adjustment is typically recommended for doxycycline in pregnancy due to minimal pharmacokinetic changes; however, use is generally avoided in the second and third trimesters. If indicated, standard dosing may be used in the first trimester with caution.
Pregnancy is a contraindication; ARESTIN should not be used. Pharmacokinetic changes in pregnancy (increased volume of distribution, enhanced clearance) may reduce minocycline levels, but no dose adjustments are recommended because the drug is contraindicated. No studies establish safe dosing in pregnancy.
ACTICLATE CAP is a high-dose activated charcoal formulation used for acute poisoning or overdose. Administer within 1 hour of ingestion for optimal efficacy. Do not use in patients with impaired consciousness unless the airway is protected. Monitor for vomiting and ensure rapid administration via nasogastric tube if necessary. Not effective for alcohols, metals, or caustics.
ARESTIN (minocycline microspheres) is a locally administered antibiotic adjunct to scaling and root planing (SRP) for periodontitis. Do not use in patients with known hypersensitivity to tetracyclines. Avoid placement in areas with active abscesses. Apply only into periodontal pockets ≥5 mm. Do not pack deeply; overfill may cause tissue irritation. No systemic antibiotic effect; monitor for local adverse effects like pain or swelling.
Take ACTICLATE CAP only if directed by a healthcare professional after a poisoning or overdose.,This medication is not for regular use; it is a one-time emergency treatment.,Avoid taking this with food or drinks; take on an empty stomach for best absorption of toxins.,You may experience black stools or vomiting; this is normal.,Seek immediate medical attention if you have trouble swallowing, severe vomiting, or signs of bowel obstruction.
Do not brush, floss, or use interdental cleaners in the treated area for 7 days after application.,Avoid eating hard, crunchy, or sticky foods for 1 week to prevent dislodging the microspheres.,Some minor discomfort, redness, or swelling at the application site is normal and usually resolves within days.,Report severe pain, swelling, or signs of infection (e.g., pus, fever) to your dentist promptly.,Continue routine oral hygiene in untreated areas as directed by your dentist.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACTICLATE CAP vs ARESTIN, answered by our medical review team.
ACTICLATE CAP is a Tetracycline Antibiotic that works by Inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, blocking aminoacyl-t RNA binding.. ARESTIN is a Tetracycline Antibiotic that works by Minocycline is a semisynthetic tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the addition of amino acids to the elongating peptide chain. This action is bacteriostatic. In periodontal disease, it also inhibits matrix metalloproteinases (MMPs), particularly collagenase, and suppresses inflammatory cytokine production, reducing tissue destruction.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACTICLATE CAP and ARESTIN depend on the specific clinical indication. These are both Tetracycline Antibiotic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACTICLATE CAP is: 350 mg orally once daily, increased to 350 mg twice daily if no response after 2 weeks.. The standard adult dose of ARESTIN is: 1 mg subgingival application per periodontal pocket, applied as a single dose by a dental professional.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACTICLATE CAP and ARESTIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACTICLATE CAP is classified as Category C. First trimester: Category D; tetracyclines can cause fetal harm including inhibited bone growth and discoloration of teeth (yellow-gray-brown). Second and third trimesters: Known t. ARESTIN is classified as Category C. ARESTIN (minocycline hydrochloride) is a tetracycline antibiotic. Class D: Positive evidence of human fetal risk. Use contraindicated in pregnancy. Risk is highest in second and th. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.